During the past decade, Hôpital Henri Mondor conducted 464 clinical trials. In the 10-year time frame, 464 clinical trials started and 88 clinical trials were completed, i.e. on average, 19% percent of trials that started reached the finish line to date. In the past 5 years, 222 clinical trials started and 66 clinical trials were completed. i.e. 29.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hôpital Henri Mondor" #1 sponsor was "Assistance Publique - Hôpitaux de Paris" with 133 trials, followed by "The Lymphoma Academic Research Organisation" with 40 trials sponsored, "UNICANCER" with 27 trials sponsored, "Celgene" with 20 trials sponsored and "Groupe Francophone des Myelodysplasies" with 20 trials sponsored. Other sponsors include 553 different institutions and companies that sponsored additional 231 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hôpital Henri Mondor" #1 collaborator was "Ministry of Health, France" with 16 trials as a collaborator, "National Cancer Institute, France" with 12 trials as a collaborator, "Roche Pharma AG" with 11 trials as a collaborator, "Novartis" with 10 trials as a collaborator and "Institut National de la Santé Et de la Recherche Médicale, France" with 9 trials as a collaborator. Other collaborators include 506 different institutions and companies that were collaborators in the rest 401 trials.

According to Clinical.Site data, the most researched conditions in "Hôpital Henri Mondor" are "Prostate Cancer" (18 trials), "Multiple Myeloma" (16 trials), "Myelodysplastic Syndromes" (12 trials), "Colorectal Cancer" (11 trials) and "Lymphoma" (11 trials). Many other conditions were trialed in "Hôpital Henri Mondor" in a lesser frequency.

Most popular intervention types in "Hôpital Henri Mondor" are "Drug" (445 trials), "Other" (157 trials), "Device" (81 trials), "Procedure" (78 trials) and "Biological" (40 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (76 trials), "Rituximab" (25 trials), "Lenalidomide" (14 trials), "Gemcitabine" (12 trials) and "Cyclophosphamide" (11 trials). Other intervention names were less common.

The vast majority of trials in "Hôpital Henri Mondor" are 748 trials for "All" genders, 30 trials for "Male" genders and 16 trials for "Female" genders.

Currently, there are 237 active trials in "Hôpital Henri Mondor". 19 are not yet recruiting, 153 are recruiting, 64 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 385 completed trials in Hôpital Henri Mondor, 1 suspended trials, and 75 terminated clinical trials to date.

Out of the total trials that were conducted in Hôpital Henri Mondor, 50 "Phase 1" clinical trials were conducted, 213 "Phase 2" clinical trials and 244 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 21 trials, and there were also 144 trials that are defined as “Not Applicable".